Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

Table 2

Risk factors for tractional retinal detachment*.

Risk factor	𝑃	CI 95%
More than 15 years from the diagnosis of diabetes mellitus	.009^‡	0.10–0.83
More than 13 days from injection to vitrectomy	.0001^‡	3.4–29
Use of a higher dose (2.5 mg) of bevacizumab	.022^‡	1.05–7.18
Diabetes Type	.833	0.34–2.20
Fibrovascular proliferation	.260	0.38–12.15
History of smoking	.408	0.11–2.41
History of HTA	.534	0.29–1.87
Prior Myocardial Infarction	.10	0.088–2.73
Prior Cerebrovascular Accident	.51	0.33–14.7
Total Cholesterol	.895	0.16–4.53
Triglycerides	.453	0.08–9.12
Hemoglobin levels	.796	0.07–4.40
Macular Thickness of DME	.123	0.33–11.65
Preretinal Hemorrhage	.317	0.33–17.5
Vitreous Hemorrhage	.292	0.24–1.47
Previous vitrectomy	.632	0.49–24.97

*DME: Diabetic Macular Edema; TRD: Tractional Retinal Detachment; HTA: Hypertension.
^‡Statistically significant.